RBC Capital Maintains Outperform Rating on Johnson & Johnson
RBC Capital maintained its $280 price target. The target implies 12.6% upside from Johnson & Johnson’s Oct. 13 close of $248.61.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.
News Feed
2 results loaded, newest first. End of these results.
RBC Capital Maintains Outperform on Johnson & Johnson, Sets Target at $290
RBC Capital reaffirmed its Outperform rating on Johnson & Johnson's stock, setting a price target of $290.00. This target represents a potential upside of 14.7% from the stock's closing price of $252.93 on October 5. The analyst note highlighted strong performance within the company's Innovative Medicines segment.